Is SEID Dead?
A recent CDC "phoner" hosted by CDC's Beth Unger included presentations by three members of the IOM committee who prepared the IOM report on ME/CFS. The committee chairwoman Ellen Clayton and doctors Lucinda Bateman and Peter Rowe were asked by an anonymous emailer if they would do anything differently today. All three said they would have dropped the suggestion to rename the disease SEID, (for Systemic Exertion Intolerance Disease). The controversy surrounding the name overshadowed important information for clinicians to enable them to diagnose the disease, the reports' strength.
The Fate and Fortunes of the Lazarus drug, Part Four
What is Ampligen? It turns out Ampligen may well be so much more than a therapy for the pandemic disease ME. Ampligen's manufacturer and patent holder, Hemipsherx Biopharma, is moving forward with plans to repurpose the drug in other diseases , including myriad cancers. Scientists who are experimenting with new uses for the drug discuss their work--and why they think Ampligen could be the next big thing. Bonus content: Tom Equels, Polymath? Last in a series of four articles on the Fate and Fortunes of the Lazarus Drug.
The Fate and Fortunes of the Lazarus Drug, Part Three
The third in a series of four articles focuses on the Fate and Fortunes of the Lazarus Drug. Ampligen's relatively new Chief Executive Officer, Tom Equels, is "repurposing" Ampligen in infectious diseases and cancer. Equels says his ultimate goal remains the approval of Ampligen for therapeutic intervention in ME. The Food and Drug Administration's years' long intransigence and it's history of bias against ME, is outlined, as is the early history of Ampligen as an experimental drug for AIDS.
The Fate and Fortunes of the Lazarus Drug, Part Two
After a near thirty-year effort by it's manufacturer, Hemispherx Biopharma, to achieve Food and Drug Administration approval for Ampligen's use as a first-line therapy for myalgic encephalomyelitis, the drug is all but unavailable in the U.S. to patients. A significant price hike and rigid enforcement of dosing protocols by the company has put the drug out of reach. Even at its height, FDA's stance on the drug made it accessible only to the very rich, or the very desperate. At no time in history has the drug been available to any more than .05 or .1 percent of the ME population. A requiem for Ampligen and its inventor, William Carter.
The Fate and Fortunes of the Lazaurus Drug, Part One
Ampligen is all but unavailable in the United States, but a small group of Canadian patients are seeking to push their government toward approving the drug for what could be an exploding Canadian patient population. An inside look at the first meeting between of Hemispherx executives and Canadian activists to discuss strategy.
Q&A with Jose Montoya of Stanford about Cytokines, T cells, Journal Reviewers and NIH
Dr. Jose Montoya talks about the new cytokine paper linking severity of symtoms with inflammation in ME; the likelihood of a diagnostic test resulting from the study; how reviewers changed the paper; the NIH funding problem; and unpublished work on T cells that may aid or result in identification of an ME pathogen,
New Kind of Analysis Yields Promise of Diagnostic Test
In advance of the high-powered ME jamboree underway at Stanford this weekend it seems right to take a close look at the paper, published on July 31, on cytokine expression in the disease.
Jose Montoya and the Stanford Experience (Final Part - Four)
It only took 30 years: from antagonism at major California medical centers in the mid-1980s to Stanford's warm embrace of M.E. by 2014. Missed opportunities, male chauvinism and scientific bias--with a happy outcome.
Jose Montoya and the Stanford Experience (Part Three)
Montoya discusses the complex issues of treatment in M.E., including confounding factors like duration of illness and degree of severity. And he volunteers a worthy proposal with the power to result in rapid progress and likely rapid resolution of this disease.
Jose Montoya and the Stanford Experience (Part Two)
“Eventually, it was just one ‘Wow’ after another,” Jose Montoya recalled in a lengthy interview. The “Wows” were uttered by colleagues as he presented them with mounting evidence of biological abnormalities in M.E. sufferers.
Stanford Then and Now: An Interview with Stanford's Jose Montoya (Part One)
One Stanford doctor, Jose Montoya, quietly rebelled in the early 2000s, eventually bringing M.E. sufferers into Stanford’s infectious disease clinic surreptitiously. Johnson unravels the remarkable story of how Montoya, over a period of years, altered the Stanford ecosystem in the realm of M.E.
Numerology (Part Three): What did they know and when did they know it?
The year 1989 was a remarkable one for the discovery process in M.E. Using imaging technologies that surpassed the MRI scan for sensitivity and specificity, California investigators found overwhelming evidence of brain damage.
Francis Collins: Should M.E. Sufferers Care Whether He Leads the NIH? (Part Two)
An assessment of Francis Collins' leadership in the struggle to recognize M.E. as a serious disease and fund it appropriately. In Johnson’s view Collins has failed on both counts.
NIH Director Francis Collins: A Trump Fave or A PlaceHolder? And Does it Matter? (Part One)
Is Francis Collins' fate important to M.E. sufferers? Consider the possibilities in this report on the politics of science and leadership at the nation's premiere research institution, and the often opaque Trump agenda.
Numerology (Part Two)
By the late 1980s, the pedantic Stephen Straus of NIH was working to shore up his psychoneurotic theory of the disease. Scientists outside NIH were raising alarms about its serious and apparently transmissible nature.
Numerology (Part One)
How many years have passed since the world-wide M.E. epidemic began--and when did it begin? In five parts, high water marks of the early days of pandemic spread.
Carol Head: Leader for a New Era (Part Two)
In her follow-up report on Carol Head, president of the largest and oldest patient organization in the U.S., Hillary Johnson reports on the reasons Solve ME/CFS returned to patient advocacy after years of exclusive attention to research.
Carol Head: Leader for a New Era (Part One)
Carol Head, president of Solve ME/CFS, is a relatively new voice in the M.E. cosmos of the last several decades, but hers is among the most urgent and creative voices to enter the fray on the advocacy side. What drives Carol Head?
Remembering Gilda Radner
“It was as if the subject of M.E. was somehow forbidden... Yet for Gilda and for me, it had been our private obsession, a topic we gave nearly equal time, cared deeply about…” Hillary Johnson remembers Gilda.
Postcards from the Edge (Of Florida)
A troubled field of inquiry, a wild and wooly mix of scientists, policy makers, "thought leaders," journalists and patient advocates made for the predictably fascinating mash-up described in this post about the 12th IACFS meeting (since 1996) in Ft. Lauderdale. The author contributes a photo gallery of some of the players in this tableau.
Can a Leopard Change its Spots?
Hillary Johnson talks to Edward Shorter, one of the most widely-published M.E.-deniers aside from the UK’s Simon Wessely.
From Idiocy to Alarm: The NIH hears from Naysayer Ed Shorter on the History of M.E.
On November 8, 2017, Canadian Edward Shorter, notorious M.E. hater and author of 1992 screed From Paralysis to Fatigued, addressed scientists involved in the first NIH clinical study of the disease in 29 years. NIH: tone deaf and apparently still clueless?